Literature DB >> 24935378

miR-186 regulates glycolysis through Glut1 during the formation of cancer-associated fibroblasts.

Pan Sun1, Jun-Wei Hu, Wu-Jun Xiong, Jun Mi.   

Abstract

Emerging evidence has suggested that glycolysis is enhanced in cancer-associated fibroblasts (CAF), and miR-186 is downregulated during the CAF formation. However, it is not clear whether miR-186 is involved in the regulation of glycolysis and what the role of miR-186 plays during the CAF formation. In this study, quantitative PCR analysises show miR-186 is downregulated during the CAF formation. Moreover, miR-186 targets the 3' UTR of Glut1, and its overexpression results in the degradation of Glut1 mRNA, which eventually reduces the level of Glut1 protein. On the other hand, knockdown of miR-186 increased the expression of Glut1. Both time course and dose response experiments also demonstrated that the protein and mRNA levels of Glut1 increase during CAF formation, according to Western blot and quantitative PCR analyses, respectively. Most importantly, besides the regulation on cell cycle progression, miR-186 regulates glucose uptake and lactate production which is mediated by Glut1. These observations suggest that miR-186 plays important roles in glycolysis regulation as well as cell cycle checkpoint activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935378     DOI: 10.7314/apjcp.2014.15.10.4245

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  20 in total

1.  The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

Authors:  Mengjia He; Qianni Jin; Cong Chen; Yifeng Liu; Xiangsen Ye; Yulin Jiang; Feihu Ji; Husun Qian; Delu Gan; Shujun Yue; Wei Zhu; Tingmei Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

2.  Overexpression of hsa-miR-186 induces chromosomal instability in arsenic-exposed human keratinocytes.

Authors:  Jiguo Wu; Ana P Ferragut Cardoso; Vanessa A R States; Laila Al-Eryani; Mark Doll; Sandra S Wise; Shesh N Rai; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2019-06-06       Impact factor: 4.219

3.  Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors.

Authors:  Maonan Wang; Xin Xia; Wenxiang Chu; Liyan Xia; Tao Meng; Lintao Liu; Yushi Liu
Journal:  Int J Clin Exp Med       Date:  2015-12-15

4.  microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2.

Authors:  Wei He; Jianfang Feng; Yan Zhang; Yuanyuan Wang; Wenqiao Zang; Guoqiang Zhao
Journal:  Lab Invest       Date:  2015-11-16       Impact factor: 5.662

5.  MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1.

Authors:  Jia-Ying Fan; Yan Yang; Jing-Ying Xie; Yan-Ling Lu; Kun Shi; Yan-Qing Huang
Journal:  Tumour Biol       Date:  2015-12-11

6.  MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C.

Authors:  Xuefeng He; Jigen Ping; Duangai Wen
Journal:  Exp Ther Med       Date:  2017-08-08       Impact factor: 2.447

Review 7.  CAF cellular glycolysis: linking cancer cells with the microenvironment.

Authors:  Amrita Roy; Soumen Bera
Journal:  Tumour Biol       Date:  2016-04-13

8.  MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.

Authors:  Kai-Xuan Sun; Jin-Wen Jiao; Shuo Chen; Bo-Liang Liu; Yang Zhao
Journal:  J Ovarian Res       Date:  2015-12-02       Impact factor: 4.234

9.  Genetic alterations and epigenetic alterations of cancer-associated fibroblasts.

Authors:  Heng Du; Guowei Che
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

10.  Inhibition of miR-186-5p contributes to high glucose-induced injury in AC16 cardiomyocytes.

Authors:  Jiamei Jiang; Hailiang Mo; Chang Liu; Bin Wu; Zijun Wu; Xingyue Li; Teng Li; Songjian He; Shanghai Li; Qiong You; Keng Wu; Runmin Guo
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.